Trial Profile
A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Darotropium bromide (Primary) ; Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 02 Jul 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.
- 26 May 2008 New trial record.